Trinity Biotech ROE 2010-2024 | TRIB
Current and historical return on equity (ROE) values for Trinity Biotech (TRIB) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Trinity Biotech ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2024-09-30 | $-0.02B | $-0.03B | 82.35% |
| 2024-06-30 | $-0.02B | $-0.03B | 98.92% |
| 2024-03-31 | $-0.02B | $-0.02B | 117.33% |
| 2023-12-31 | $-0.03B | $-0.02B | 169.49% |
| 2023-09-30 | $-0.03B | $-0.02B | 313.51% |
| 2023-06-30 | $-0.03B | $-0.01B | 953.85% |
| 2023-03-31 | $-0.04B | $-0.01B | -1000.00% |
| 2022-12-31 | $-0.04B | $0.00B | -1093.33% |
| 2022-09-30 | $-0.03B | $0.01B | -752.94% |
| 2022-06-30 | $-0.02B | $0.02B | -800.00% |
| 2022-03-31 | $-0.01B | $-0.01B | 1040.00% |
| 2021-12-31 | $0.00B | $0.00B | 400.00% |
| 2021-09-30 | $-0.01B | $0.00B | 3200.00% |
| 2021-06-30 | $0.00B | $0.00B | -160.00% |
| 2021-03-31 | $0.00B | $0.00B | -200.00% |
| 2020-12-31 | $-0.01B | $0.00B | -480.00% |
| 2020-09-30 | $-0.02B | $0.01B | -633.33% |
| 2020-06-30 | $-0.03B | $0.00B | -236.36% |
| 2020-03-31 | $-0.03B | $0.00B | -142.86% |
| 2019-12-31 | $-0.03B | $0.01B | -88.19% |
| 2019-09-30 | $-0.03B | $0.04B | -69.88% |
| 2019-06-30 | $-0.03B | $0.04B | -57.44% |
| 2019-03-31 | $-0.02B | $0.04B | -39.46% |
| 2018-12-31 | $-0.02B | $0.04B | -35.92% |
| 2018-09-30 | $-0.04B | $0.07B | -61.65% |
| 2018-06-30 | $-0.04B | $0.07B | -55.26% |
| 2018-03-31 | $-0.04B | $0.07B | -48.84% |
| 2017-12-31 | $-0.04B | $0.07B | -42.38% |
| 2017-09-30 | $-0.10B | $0.11B | -91.88% |
| 2017-06-30 | $-0.10B | $0.11B | -74.77% |
| 2017-03-31 | $-0.10B | $0.11B | -61.97% |
| 2016-12-31 | $-0.10B | $0.11B | -54.45% |
| 2016-09-30 | $0.00B | $0.21B | 1.42% |
| 2016-06-30 | $0.02B | $0.21B | 7.55% |
| 2016-03-31 | $0.02B | $0.21B | 8.08% |
| 2015-12-31 | $0.02B | $0.21B | 10.59% |
| 2015-09-30 | $0.02B | $0.21B | 11.30% |
| 2015-06-30 | $0.02B | $0.21B | 7.52% |
| 2015-03-31 | $0.02B | $0.20B | 8.11% |
| 2014-12-31 | $0.02B | $0.20B | 8.24% |
| 2014-09-30 | $0.02B | $0.20B | 8.91% |
| 2014-06-30 | $0.01B | $0.20B | 5.38% |
| 2014-03-31 | $0.01B | $0.19B | 5.54% |
| 2013-12-31 | $0.01B | $0.18B | 5.65% |
| 2013-09-30 | $0.01B | $0.18B | 5.19% |
| 2013-06-30 | $0.02B | $0.18B | 9.36% |
| 2013-03-31 | $0.02B | $0.18B | 9.57% |
| 2012-12-31 | $0.02B | $0.17B | 9.80% |
| 2012-09-30 | $0.02B | $0.17B | 10.08% |
| 2012-06-30 | $0.02B | $0.16B | 10.34% |
| 2012-03-31 | $0.02B | $0.16B | 10.56% |
| 2011-12-31 | $0.02B | $0.15B | 10.81% |
| 2011-09-30 | $0.02B | $0.15B | 11.00% |
| 2011-06-30 | $0.02B | $0.15B | 10.53% |
| 2011-03-31 | $0.06B | $0.15B | 44.60% |
| 2010-12-31 | $0.06B | $0.14B | 49.49% |
| 2010-09-30 | $0.06B | $0.14B | 55.68% |
| 2010-06-30 | $0.06B | $0.13B | 64.86% |
| 2010-03-31 | $0.01B | $0.08B | 15.53% |
| 2009-12-31 | $0.01B | $0.08B | 16.33% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.015B | $0.057B |
| Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $231.085B | 27.79 |
| Boston Scientific (BSX) | United States | $155.238B | 38.86 |
| Stryker (SYK) | United States | $144.362B | 30.18 |
| EssilorLuxottica (ESLOY) | France | $132.860B | 0.00 |
| Medtronic (MDT) | Ireland | $108.824B | 15.89 |
| Lonza Group Ag (LZAGY) | Switzerland | $52.624B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.259B | 27.44 |
| ResMed (RMD) | United States | $35.183B | 26.43 |
| GE HealthCare Technologies (GEHC) | United States | $32.295B | 15.33 |
| Agilent Technologies (A) | United States | $30.971B | 20.46 |
| Terumo (TRUMY) | Japan | $29.019B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.053B | 17.17 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.255B | 12.80 |
| Insulet (PODD) | United States | $18.084B | 77.18 |
| Baxter (BAX) | United States | $15.752B | 11.77 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.535B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $7.970B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $7.447B | 18.31 |
| Bio-Rad Laboratories (BIO) | United States | $6.620B | 22.38 |
| Prestige Consumer Healthcare (PBH) | United States | $4.171B | 19.90 |
| Perrigo (PRGO) | Ireland | $3.497B | 10.01 |
| ICU Medical (ICUI) | United States | $3.486B | 29.69 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.208B | 15.10 |
| Envista Holdings (NVST) | United States | $2.880B | 23.93 |
| GN Store Nord (GNNDY) | Denmark | $2.068B | 17.13 |
| QuidelOrtho (QDEL) | United States | $1.964B | 16.45 |
| LeMaitre Vascular (LMAT) | United States | $1.778B | 39.75 |
| AtriCure (ATRC) | United States | $1.486B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.374B | 21.63 |
| Neogen (NEOG) | United States | $1.248B | 15.97 |
| Kestra Medical Technologies (KMTS) | United States | $1.220B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.200B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.184B | 11.40 |
| InMode (INMD) | Israel | $1.013B | 9.28 |
| Phibro Animal Health (PAHC) | United States | $0.789B | 12.10 |
| Evolus (EOLS) | United States | $0.779B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.637B | 0.00 |
| CeriBell (CBLL) | United States | $0.588B | 0.00 |
| Owens & Minor (OMI) | United States | $0.580B | 4.94 |
| Valneva SE (VALN) | France | $0.549B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.542B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.526B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.458B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.442B | 0.00 |
| Omeros (OMER) | United States | $0.418B | 0.00 |
| Surmodics (SRDX) | United States | $0.395B | 0.00 |
| SNDL (SNDL) | Canada | $0.365B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.359B | 15.55 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.296B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.292B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.291B | 26.32 |
| Aurora Cannabis (ACB) | Canada | $0.272B | 48.40 |
| Sanuwave Health (SNWV) | United States | $0.264B | 0.00 |
| ZimVie (ZIMV) | United States | $0.261B | 15.60 |
| Cerus (CERS) | United States | $0.258B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.245B | 0.00 |
| Quanterix (QTRX) | United States | $0.233B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.231B | 0.00 |
| High Tide (HITI) | Canada | $0.194B | 0.00 |
| Biote (BTMD) | United States | $0.190B | 4.35 |
| Utah Medical Products (UTMD) | United States | $0.173B | 13.93 |
| Brainsway (BWAY) | Israel | $0.170B | 53.06 |
| TriSalus Life Sciences (TLSI) | United States | $0.165B | 0.00 |
| Organigram Global (OGI) | Canada | $0.154B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.148B | 18.22 |
| Jin Medical (ZJYL) | China | $0.119B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.116B | 0.00 |
| MacroGenics (MGNX) | United States | $0.110B | 0.00 |
| Exagen (XGN) | United States | $0.108B | 0.00 |
| Agape ATP (ATPC) | $0.099B | 0.00 | |
| Oramed Pharmaceuticals (ORMP) | United States | $0.095B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.094B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.70 |
| Jushi Holdings (JUSHF) | United States | $0.076B | 0.00 |
| Veru (VERU) | United States | $0.075B | 0.00 |
| InterCure (INCR) | Israel | $0.073B | 0.00 |
| Zynex (ZYXI) | United States | $0.070B | 0.00 |
| United Health Products (UEEC) | United States | $0.064B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.059B | 0.00 |
| ImmuCell (ICCC) | United States | $0.048B | 0.00 |
| Apyx Medical (APYX) | United States | $0.047B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.042B | 61.50 |
| United-Guardian (UG) | United States | $0.037B | 11.28 |
| Safety Shot (SHOT) | United States | $0.036B | 0.00 |
| Nephros (NEPH) | United States | $0.020B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |